LivaNova PLC
$ 77.17
3.17%
09 Jun - close price
- Market Cap 4,109,029,000 USD
- Current Price $ 77.17
- High / Low $ 77.80 / 75.95
- Stock P/E 38.16
- Book Value 22.06
- EPS 1.96
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.10 %
- 52 Week High 77.78
- 52 Week Low 41.02
About
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Analyst Target Price
$80.60
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-25 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-11-01 | 2023-07-26 |
| Reported EPS | 0.98 | 0.86 | 1.11 | 1.05 | 0.88 | 0.81 | 0.9 | 0.93 | 0.73 | 0.87 | 0.73 | 0.78 |
| Estimated EPS | 0.9 | 0.8104 | 0.92 | 0.87 | 0.76 | 0.8006 | 0.72 | 0.78 | 0.49 | 0.77 | 0.64 | 0.54 |
| Surprise | 0.08 | 0.0496 | 0.19 | 0.18 | 0.12 | 0.0094 | 0.18 | 0.15 | 0.24 | 0.1 | 0.09 | 0.24 |
| Surprise Percentage | 8.8889% | 6.1204% | 20.6522% | 20.6897% | 15.7895% | 1.1741% | 25% | 19.2308% | 48.9796% | 12.987% | 14.0625% | 44.4444% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.09 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LIVN
2026-06-09 14:10:11
LivaNova stock reached a 52-week high of $76.92, currently trading at $74.80 with a market capitalization of $4.11 billion. The stock has shown a significant 61.56% return over the past year and is considered undervalued by InvestingPro Fair Value analysis. This performance follows strong Q1 2026 earnings, which surpassed analyst expectations, and recent strategic personnel appointments.
2026-06-09 02:09:42
LivaNova PLC (LIVN) stock rose 3.4% to $74.80, but GuruFocus's GF Value indicates it is 20.0% overvalued at $62.31. Despite a GF Score of 77/100, showing overall strong performance, recent insider selling suggests caution. Investors are advised to wait for a price adjustment closer to its intrinsic value.
2026-06-06 16:39:11
LivaNova plc (NASDAQ:LIVN) reported strong first-quarter results, exceeding Wall Street expectations for both adjusted earnings per share and revenue. Despite raising its full-year revenue and adjusted EPS guidance, the stock fell over 2% in pre-market trading, likely due to the midpoint of the new EPS guidance being only slightly above consensus estimates. The medical technology company saw significant growth in its Cardiopulmonary and Neuromodulation segments, and achieved a key regulatory milestone with FDA approval for its aura6000 System for obstructive sleep apnea.
2026-06-05 13:39:37
LivaNova PLC has appointed Anne Liddy as its new Chief Legal Officer, effective August 31, where she will oversee global legal and compliance functions and join the Executive Leadership Team. Liddy brings over 20 years of legal and compliance experience in the healthcare and life sciences sectors, previously serving as General Counsel at Hologic, Inc. This leadership addition comes as the medical technology company, valued at $4.05 billion, is trading near its 52-week high and is considered undervalued by InvestingPro analysis, following a strong Q1 2026 performance.
2026-06-05 12:39:37
LivaNova PLC has announced the appointment of Anne Liddy as Chief Legal Officer, effective August 31, where she will oversee the company's global legal and compliance functions and join the Executive Leadership Team. Liddy brings over two decades of experience from Hologic, Inc. and Pfizer, Inc., specializing in legal, regulatory, M&A, and compliance matters for healthcare and life sciences companies. CEO Vladimir Makatsaria highlighted Liddy's expertise and leadership as instrumental in advancing LivaNova's business and innovation goals.
2026-06-05 07:40:17
LivaNova (NASDAQ:LIVN) reported strong first-quarter 2026 results, surpassing analyst expectations with adjusted EPS of $0.98 and revenue of $362.3 million. This performance, driven by double-digit growth in both Cardiopulmonary and Neuromodulation segments and the FDA approval of its aura6000 System for obstructive sleep apnea, led the company to raise its full-year 2026 guidance. Investors responded positively, with shares increasing over 6% in premarket trading.
